Royal Bank of Canada Forecasts Strong Price Appreciation for DRI Healthcare Trust (TSE:DHT.UN) Stock

DRI Healthcare Trust (TSE:DHT.UN) had its price objective raised by equities research analysts at Royal Bank of Canada from C$17.00 to C$18.00 in a report issued on Thursday,BayStreet.CA reports. The firm currently has an “outperform” rating on the stock. Royal Bank of Canada’s target price would indicate a potential upside of 42.41% from the stock’s current price.

DHT.UN has been the subject of a number of other reports. CIBC increased their price target on DRI Healthcare Trust from C$16.00 to C$17.00 and gave the company an “outperform” rating in a research note on Thursday. National Bankshares increased their price target on DRI Healthcare Trust from C$18.00 to C$18.50 and gave the company an “outperform” rating in a research note on Thursday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of C$18.07.

DRI Healthcare Trust Stock Up 0.6%

Shares of TSE DHT.UN opened at C$12.64 on Thursday. The stock has a fifty day moving average price of C$11.66 and a two-hundred day moving average price of C$11.99. DRI Healthcare Trust has a 1 year low of C$10.39 and a 1 year high of C$16.26.

About DRI Healthcare Trust

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term.